HC Wainwright Trims Aclaris Therapeutics (NASDAQ:ACRS) Target Price to $9.00

Aclaris Therapeutics (NASDAQ:ACRS – Free Report) had its target price decreased by HC Wainwright from $43.00 to $9.00 in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2023 earnings at ($0.50) EPS, […]

Leave a Reply

Your email address will not be published.

Previous post Akero Therapeutics’ (AKRO) “Buy” Rating Reiterated at HC Wainwright
Next post Orioles sign Jorge Mateo, 3 others to 2024 deals, tender contracts to remaining 13 arbitration-eligible players